Hudson Bay Capital Management
IMVT icon

Hudson Bay Capital Management’s Immunovant IMVT Stock Holding History

Hudson Bay Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-184,600
Closed -$3.5M – 861
2023
Q2 		$3.5M Buy
+184,600
New +$3.44M 0.03% 393

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Hudson Bay Capital Management's IMVT Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of Immunovant (IMVT) in Q2 2026, closing a stake of 19,230 shares — an estimated $478K sold.

Hudson Bay Capital Management first reported a position in IMVT in Q3 2024 and held it in 6 quarters. The position peaked at $2.76M in Q1 2025. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Hudson Bay Capital Management reported no remaining Immunovant position as of Q2 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 19,230 Immunovant shares in Q2 2026, an estimated $478K.
  • Hudson Bay Capital Management first reported a position in Immunovant in Q3 2024 and held it in 6 quarters.
  • Hudson Bay Capital Management's Immunovant position peaked at $2.76M in Q1 2025.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.